Creating innovative bio-convergent technologies for better human life

1. 제목: BST 204, Herbal Medicinal Product for the treatment of Cancer Cachexia


2. 연사: 유영효 (녹십자 웰빙 대표이사)


3. 일시: 2016. 11. 30 (수요일) PM 4:30 ~ 5:45


4. 장소: E16 정문술빌딩 드림홀


5. 초록
Panax ginseng C. A. Meyer and herbal preparations made thereof are traditionally used for treatment of symptoms of asthenia such as fatigue and weakness. The reflection paper on the adaptogenic concept considers Panax Ginseng C.A. Meyer as an herbal adaptogen. Adaptogens may enable an increased work capacity that is not followed by a decrease and may facilitate the ability of an organism to adapt to environmental factors and to avoid damage from such factors . The pharmacological properties of Ginseng are generally attributed to its triterpene glycosides, called ginsenosides. Ginsenosides are mainly dammarane-skeleton triterpene saponins derived from protopanaxadiol, protopanaxtriol and oleanolic acid.
Evidence supporting that ginseng and the ginsenosides, resp., may be beneficial in patients suffering from Cachexia and Cancer Related Fatigue (CRF) comes from non-clinical data. The investigations of the primary pharmacodynamics (PDs) of BST204, i.e. its anti-fatigue activity, focused on the Running Wheel Activity Test. These are considered appropriate and accepted animal models of fatigue related to cancer and anti-cancer treatments. Animal studies have shown improved endurance and swimming duration time with ginseng, specifically ginsenosides. In animals significantly affected by tumor burden and anti-cancer drugs (i.e. elevation of serum concentrations of TNF-alpha and IL-6), the treatment with 200mg/kg BST204 resulted in a significant decrease of the serum concentration of both cytokines compared to control animals not treated with BST204. BST204 caused a significant reversal of pathological changes of hematology parameters induced by xenografting and anti-cancer drugs. Tests of cardiovascular, respiratory and CNS safety were performed according to GLP and in agreement with current European guidance. In vitro and in vivo studies did not discern any adverse findings for BST204. Effects on cardiac repolarisation were studied and did not yielding any undesirable finding. proposed as underlying CRF include 5-HT neurotransmitter dysregulation, vagal afferent . activation, alterations in muscle and ATP metabolism, hypothalamic–pituitary–adrenal axis dysfunction, and cytokine dysregulation ( e.g. TNF-alpha and IL-6). The rationale of the study to be undertaken was to obtain data on the first use of BST204 in humans and to investigate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of BST204. Furthermore, the effect of food was investigated in a crossover design. Thus information obtained on the such aspects will be discussed.


– 문의: 이도헌 교수 (4316)